Analysis
Dren Bio has closed an oversubscribed $350 million private financing, co-led by Juvia Group and Lightspeed Venture Partners, to push its lead cancer antibody toward regulators and expand its broader immunology pipeline, the clinical-stage biotech said.
What does Dren Bio do?
Dren Bio is a clinical-stage biopharmaceutical company developing multispecific antibodies designed to trigger controlled depletion of disease-causing cells through the body's own myeloid cells, according to the company. Its lead candidate, dibotatug, is an investigational monoclonal antibody targeting CD94 that depletes pathogenic cytotoxic cells while sparing the rest of the immune system; more than 300 patients have been dosed in Phase 1/2 studies for cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, two rare blood cancers with no approved therapies, Pulse2 reported. Nenad Tomasevic is the company's founder and chief executive.
How much has Dren Bio raised?
Dren Bio has leaned on pharma partnerships as much as venture rounds to fund its pipeline:
“Named head-to-head competitors in CD94-targeted or myeloid-engager therapeutics were not available in the sources reviewed for this story.”
- Pfizer collaboration — deal valued at more than $1B, including a $25M upfront payment
- Sanofi collaboration, December 2025 — $100M upfront payment, up to $1.7B more in milestones, for a next-generation B-cell depletion therapy, according to a Dren Bio release
- This week's private financing — $350M, its largest disclosed equity raise to date, though the company has not disclosed a post-money valuation
The company's first platform program was sold to Sanofi in May 2025.
Who invested in Dren Bio?
Juvia Group and Lightspeed Venture Partners co-led the round. New investors Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management and OrbiMed joined existing backers 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital and ArrowMark Partners, Pulse2 reported. "We believe dibotatug has the potential to dramatically change the treatment paradigm," said Sujal Shah, co-founder and managing director of Juvia Group.
Biotech funding market and competitors
The round lands in a year when precision-oncology financings have stayed resilient even as broader venture funding has tightened -- a trend Pulse tracks on its own funding tracker across hundreds of 2026 rounds. Named head-to-head competitors in CD94-targeted or myeloid-engager therapeutics were not available in the sources reviewed for this story.
The clearest comparison available is financial: Dren Bio's two prior pharma deals, the Sanofi collaboration and the Pfizer agreement worth more than $1 billion, show its platform already attracts big-pharma partners. This week's $350 million round outsizes Dren's own $25 million Pfizer upfront payment by 14 times.
The financing funds late-stage trials, regulatory filings and commercial-launch prep, Pulse2 reported, but dibotatug has not yet reported pivotal trial results or filed for approval -- an oversubscribed private round is a vote of confidence from existing backers, not a clinical or regulatory milestone.
What to watch next
The next concrete marker will be data from the ongoing Phase 1/2 studies in cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, plus any update on the platform program now licensed to Sanofi. Pulse has not previously covered Dren Bio; this financing is the company's introduction to the page.